Chemotherapy for advanced hormone refractory prostate cancer
- 1 December 1999
- Vol. 54 (6) , 30-35
- https://doi.org/10.1016/s0090-4295(99)00452-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumorsCancer, 1998
- Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.Journal of Clinical Oncology, 1998
- Expression of BCL-2 Oncoprotein and P53 Protein Accumulation in Bone Marrow Metastases of Androgen Independent Prostate CancerJournal of Urology, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cellsCancer Letters, 1995
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992